Abstract
The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Antitumor Activities of Interleukin-27 on Melanoma
Volume: 10 Issue: 1
Author(s): Hiroshi Nagai, Shuntaro Oniki, Susumu Fujiwara, Mingli Xu, Izuru Mizoguchi, Takayuki Yoshimoto and Chikako Nishigori
Affiliation:
Keywords: malignant melanoma, immunological therapies, Antitumor Activities, Interleukin-27, cytokine
Abstract: The worldwide incidence of malignant melanoma has been steadily increasing, and it has become a major public health problem in many countries. Melanoma has been considered as a prototypical “immunogenic” tumor on the basis of clinical observations showing that primary lesions can spontaneously regress and that immunosuppressed individuals have an increased incidence of melanoma. Thus, various immunological therapies have been intensively conducted for the treatment of melanoma. Interleukin(IL)-27 is a IL-12-related heterodimeric cytokine composed of p28 and EBV-induced gene 3 subunits that are structurally related to the p35 and p40 subunits of IL-12, respectively. Recent studies reveal that IL-27 exhibits not only potent antitumor immune activities via cytotoxic T lymphocytes or natural killer cells but also an antiangiogenic effect. We recently clarified that IL-27 possesses an antiproliferative activity on melanoma cells. This review summarizes antitumor responses induced by IL-27 and novel anti-melanoma activities of IL-27.
Export Options
About this article
Cite this article as:
Nagai Hiroshi, Oniki Shuntaro, Fujiwara Susumu, Xu Mingli, Mizoguchi Izuru, Yoshimoto Takayuki and Nishigori Chikako, Antitumor Activities of Interleukin-27 on Melanoma, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187153010790827920
DOI https://dx.doi.org/10.2174/187153010790827920 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aromatic Sulfonamides Containing a Condensed Piperidine Moiety as Potential Oxidative Stress-Inducing Anticancer Agents
Medicinal Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Emerging Role of GPR30/GPER1 in Skeletal Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ultra-deformable Liposomes as Flexible Nanovesicular Carrier to Penetrate Versatile Drugs Transdermally
Nanoscience & Nanotechnology-Asia Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Mini-Reviews in Organic Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry PCL/PEG Copolymeric Nanoparticles: Potential Nanoplatforms for Anticancer Agent Delivery
Current Drug Targets Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Therapeutic Use of Chemokines
Current Pharmaceutical Design Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry